| 2025-12-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.83美元,归母净利润4659.00万美元,同比去年增长18.60%
|
| 2025-12-05 |
详情>>
业绩披露：
2024年年报每股收益3.05美元,归母净利润4883.20万美元,同比去年增长2791.18%
|
| 2025-09-26 |
详情>>
业绩披露：
2025年中报每股收益1.87美元,归母净利润3071.60万美元,同比去年增长64.28%
|
| 2024-05-02 |
详情>>
股本变动：
变动后总股本6901.09万股
|
| 2024-04-05 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
4.To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended.
5.To approve the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 4.
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-14 |
财报披露：
美东时间 2024-03-14 盘后发布财报
|
| 2023-03-29 |
股东大会：
将于2023-05-17召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended;
5.To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 85,000,000 to 170,000,000 shares;
6.To approve the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5;
7.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-03-22 |
股东大会：
将于2022-04-26召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended;
5.To approve an amendment to the aTyr Pharma, Inc. 2015 Employee Stock Purchase Plan;
6.To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 42,500,000 to 85,000,000 shares;
7.To approve the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4, 5 or 6;
8.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-24 |
股东大会：
将于2021-04-28召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement;
4.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers;
5.To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan;
6.To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 21,425,000 to 42,500,000 shares;
7.To approve the authorization to adjourn the 2021 Annual Meeting of Stockholders, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 5 or Proposal 6;
8.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-01-05 |
复牌提示：
2021-01-04 16:11:27 停牌，复牌日期 2021-01-04 16:45:00
|
| 2020-04-02 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
3.To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 350,000 shares.
4.To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 10,714,286 to 21,425,000 shares.
5.To approve the authorization to adjourn the 2020 Annual Meeting of Stockholders, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3 or Proposal 4
6.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2019-07-01 |
详情>>
拆分方案：
每14.0000合并分成1.0000股
|
| 2019-03-28 |
股东大会：
将于2019-05-08召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2022 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
3.To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 1,000,000 shares.
4.To approve an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of one-for-three (1:3) to one-for-fifteen (1:15), such ratio to be determined in the sole discretion of the Board of Directors.
5.To approve the authorization to adjourn the Annual Meeting of Stockholders, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3 or Proposal 4.
6.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2018-04-03 |
股东大会：
将于2018-05-15召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, as nominated by the Board of Directors, to hold office until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.
3.To approve, under applicable NASDAQ listing rules, the issuance of 11,429,760 shares of the Company’s common stock upon the conversion of 2,285,952 outstanding shares of the Company’s Class X Convertible Preferred Stock.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2017-03-30 |
股东大会：
将于2017-05-09召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, as nominated by the Board of Directors, to hold office until the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017.
3.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2016-04-12 |
股东大会：
将于2016-05-24召开股东大会
会议内容 ▼▲
- 1.To elect the three Class I directors, as nominated by the Board of Directors, to hold office until the 2019 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
3.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2015-05-12 |
详情>>
内部人交易：
CHP II LP等共交易9笔
|